We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-15.39%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$115M
AUM Growth
-$35.6M
Cap. Flow
-$4.82M
Cap. Flow %
-4.18%
Top 10 Hldgs %
98.09%
Holding
15
New
1
Increased
7
Reduced
2
Closed
2

Top Buys

1
DERM
Dermira, Inc.
DERM
+$3.64M
2
DVAX
Dynavax Technologies
DVAX
+$2.83M
3
CMRX
Chimerix, Inc.
CMRX
+$1.7M
4
SAGE
Sage Therapeutics
SAGE
+$1.47M
5
CALA
Calithera Biosciences, Inc
CALA
+$1.06M

Top Sells

1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.42M
2
RLYP
RELYPSA INC COM
RLYP
+$4.27M
3
ESPR
Esperion Therapeutics
ESPR
+$4.07M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.53M

Sector Composition

1 Healthcare 86.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
1
DELISTED
Aravive, Inc. Common Stock
ARAV
$23.5M 20.39%
339,871
– –
ALDR
2
DELISTED
Alder Biopharmaceuticals
ALDR
$21.8M 18.89%
664,783
+7,000
+1% +$298K
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$18.6M 16.13%
1,377,497
– –
DVAX
4
DELISTED
Dynavax Technologies
DVAX
$17.5M 15.17%
712,498
+100,000
+16% +$2.83M
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
$13.6M 11.76%
355,007
+34,399
+11% +$1.7M
DERM
6
DELISTED
Dermira, Inc.
DERM
$6.57M 5.7%
281,592
+150,002
+114% +$3.64M
MRNS
7
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.88M 5.1%
176,143
+12,769
+8% +$721K
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$2.85M 2.48%
114,621
+24,883
+28% +$748K
CALA
9
DELISTED
Calithera Biosciences, Inc
CALA
$1.63M 1.41%
14,979
+8,184
+120% +$1.06M
RLYP
10
DELISTED
RELYPSA INC COM
RLYP
$1.22M 1.06%
65,961
-155,243
-70% -$4.27M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$1.01M 0.87%
+23,829
New +$1.47M
AKAO
12
DELISTED
Achaogen Inc
AKAO
$765K 0.66%
132,728
– –
KPTI icon
13
Karyopharm Therapeutics
KPTI
$216M
$431K 0.37%
2,732
-5,714
-68% -$1.53M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-177,230
Closed -$7.42M
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
– –
-49,816
Closed -$4.07M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2015 Portfolio in Review

As of Q3 2015, New Leaf Venture Partners held 15 positions worth $115M, down 24% from $151M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

New Leaf Venture Partners withdrew a net $4.82M in Q3 2015, closing 2 positions and reducing 2 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $7.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

Against the trend, New Leaf Venture Partners opened a new position in Sage Therapeutics worth $1.01M.

  • New Leaf Venture Partners's largest Q3 2015 buy was Sage Therapeutics: 23,829 shares worth $1.01M.
  • New Leaf Venture Partners added most to Dermira, Inc. in Q3 2015, an estimated $3.64M increase.
  • New Leaf Venture Partners's biggest Q3 2015 reduction was RELYPSA INC COM, cutting an estimated $4.27M.
  • New Leaf Venture Partners fully exited Acadia Pharmaceuticals in Q3 2015, selling an estimated $7.42M.
  • New Leaf Venture Partners's ten largest holdings make up 98% of its $115M portfolio in Q3 2015.
  • New Leaf Venture Partners opened 1 new position and closed 2 in Q3 2015.
  • New Leaf Venture Partners's portfolio value fell 24% quarter-over-quarter to $115M.

Based on New Leaf Venture Partners's 13F filing for Q3 2015, filed 16 Nov 2015.